AbbVie rises on news of share buy-back and beating 1st-qtr forecasts

26 April 2018
2019_biotech_test_vial_discovery_big

USA drugmaker AbbVie (NYSE: ABBV) today posted first-quarter 2018 results which beat expectations, as net revenue rose 21.4% to $7.93 billion, ahead of average estimate of $7.59 billion.

AbbVie’s shares were up 3.92% at $95.50 in late-morning trading.

Net earnings for the quarter increased to $2.78 billion, or earnkigns$1.74 per share, up from $1.71 billion, or $1.06 per share, a year earlier. Excluding special items, AbbVie earned $1.87 per share, which beat analysts’ estimate of $1.79.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology